Develops cannabinoid-based drugs for cancer and cancer anorexia cachexia syndrome.
May 2026Revenue $0.00/yrExpenses $429K/yr
No trendCash runway ≈ 1 month from May 2026
Figures by year
When will CNBX Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to May 2026, revenue was $0.00 and expenses $429K.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Aug 2025 | $0.00 | $272K | −$272K |
| Aug 2024 | $130K | $713K | −$583K |
| Aug 2023 | $410K | $1.34M | −$931K |
| Aug 2022 | $30.0K | $2.98M | −$2.95M |
| Aug 2021 | $0.00 | $2.60M | −$2.60M |
| Aug 2020 | $7.16K | $3.05M | −$3.04M |
| Aug 2019 | $9.84K | $3.31M | −$3.30M |
| Aug 2018 | $9.60K | $3.82M | −$3.81M |
| Aug 2017 | $5.68K | $1.86M | −$1.85M |
| Aug 2016 | $113K | $393K | −$281K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.